AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

The relationship between chronic obstructive pulmonary disease (COPD) and chronic bronchitis ... including diagnostic criteria and management of acute exacerbation of CB (AECB) in the elderly ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

it would be useful to have other treatments that reduced the frequency and duration of acute exacerbations. The management of individual patients with COPD should be guided by the symptoms and ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ETCompany ParticipantsPaul Hudson - Chief Executive OfficerFrancois-Xavier Roger ...

This was a prospective, parallel group, placebo-controlled, double-blind study of the efficacy of azithromycin in the chronic, outpatient management of COPD with a primary outcome of time to first ...

The hazardous air quality in Los Angeles is largely a result of smoke from the Pacific Palisades Fire, intensified by strong ...

A Palisades Fire victim who is a pulmonologist sets up a Disaster Relief Pulmonary Clinic Amidst strong winds expected on the ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...